Skip to main content

Longitudinal Imaging Reveals Tumor Uptake and Prolonged Retention of Bispecific T Cell-Engaging Antibody in GBM via Passive and Active Mechanisms.

Publication ,  Journal Article
Feng, Y; Haupt, B; Huynh, TT; Meshaw, R; Martin-Regalado, A; Thakur, A; Duffy, JT; Alzeer, A; Siegel, DA; Barnes, A; Simberg, D; Zalutsky, MR ...
Published in: Clin Cancer Res
August 14, 2025

PURPOSE: This study aimed to assess the dynamics of tumor-specific uptake, retention, and blood-tumor barrier penetration of our unique IL-13 receptor α-2 × CD3 bispecific T-cell engager (BTE) following systemic administration in mice with intracranial glioblastoma (GBM) xenografts. EXPERIMENTAL DESIGN: In vitro, BTE binding and accumulation were evaluated in glioma neurospheres. In in vivo studies, the BTEs labeled with either iodine-124 using residualizing chemistry or conjugated to Cy5 were used for longitudinal tracking in patient-derived xenograft models of GBM using PET/CT and confocal microscopy. The survival analysis in mice bearing intracranial GBM tumors was conducted to validate the findings from imaging studies. RESULTS: In vitro, the BTE demonstrated target-specific binding and accumulation in IL-13 receptor α-2-expressing glioma spheres. In vivo, PET/CT imaging revealed that the BTE reached the tumor site within 3 hours after injection, achieving up to 4.8% ID/g, with sustained tumor retention for up to 24 hours, significantly higher than background levels in surrounding normal brain tissue. Confocal microscopy confirmed BTE presence in the tumor bed extravascular space with evidence of T cell-mediated BTE transport across the blood-tumor barrier. Despite its short plasma half-life, the BTE remained in the tumor microenvironment for at least 24 hours. Mice bearing GBM6 brain tumors treated with BTE for 3 to 4 days apart via the intravenous route showed a significant survival advantage over the control group. CONCLUSIONS: Our findings provide critical insights into the pharmacokinetics of BTE molecules in GBM. They demonstrate effective penetration and prolonged intratumoral retention following a single systemic dose, supporting further exploration of BTE treatment regimens for translation to clinical settings.

Duke Scholars

Published In

Clin Cancer Res

DOI

EISSN

1557-3265

Publication Date

August 14, 2025

Volume

31

Issue

16

Start / End Page

3537 / 3549

Location

United States

Related Subject Headings

  • Xenograft Model Antitumor Assays
  • T-Lymphocytes
  • Positron Emission Tomography Computed Tomography
  • Oncology & Carcinogenesis
  • Mice
  • Iodine Radioisotopes
  • Interleukin-13 Receptor alpha2 Subunit
  • Humans
  • Glioblastoma
  • Disease Models, Animal
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Feng, Y., Haupt, B., Huynh, T. T., Meshaw, R., Martin-Regalado, A., Thakur, A., … Balyasnikova, I. V. (2025). Longitudinal Imaging Reveals Tumor Uptake and Prolonged Retention of Bispecific T Cell-Engaging Antibody in GBM via Passive and Active Mechanisms. Clin Cancer Res, 31(16), 3537–3549. https://doi.org/10.1158/1078-0432.CCR-24-4194
Feng, Yutian, Benedikt Haupt, Truc T. Huynh, Rebecca Meshaw, Angela Martin-Regalado, Aditi Thakur, Joseph T. Duffy, et al. “Longitudinal Imaging Reveals Tumor Uptake and Prolonged Retention of Bispecific T Cell-Engaging Antibody in GBM via Passive and Active Mechanisms.Clin Cancer Res 31, no. 16 (August 14, 2025): 3537–49. https://doi.org/10.1158/1078-0432.CCR-24-4194.
Feng Y, Haupt B, Huynh TT, Meshaw R, Martin-Regalado A, Thakur A, et al. Longitudinal Imaging Reveals Tumor Uptake and Prolonged Retention of Bispecific T Cell-Engaging Antibody in GBM via Passive and Active Mechanisms. Clin Cancer Res. 2025 Aug 14;31(16):3537–49.
Feng, Yutian, et al. “Longitudinal Imaging Reveals Tumor Uptake and Prolonged Retention of Bispecific T Cell-Engaging Antibody in GBM via Passive and Active Mechanisms.Clin Cancer Res, vol. 31, no. 16, Aug. 2025, pp. 3537–49. Pubmed, doi:10.1158/1078-0432.CCR-24-4194.
Feng Y, Haupt B, Huynh TT, Meshaw R, Martin-Regalado A, Thakur A, Duffy JT, Alzeer A, Siegel DA, Barnes A, Simberg D, Zalutsky MR, Balyasnikova IV. Longitudinal Imaging Reveals Tumor Uptake and Prolonged Retention of Bispecific T Cell-Engaging Antibody in GBM via Passive and Active Mechanisms. Clin Cancer Res. 2025 Aug 14;31(16):3537–3549.

Published In

Clin Cancer Res

DOI

EISSN

1557-3265

Publication Date

August 14, 2025

Volume

31

Issue

16

Start / End Page

3537 / 3549

Location

United States

Related Subject Headings

  • Xenograft Model Antitumor Assays
  • T-Lymphocytes
  • Positron Emission Tomography Computed Tomography
  • Oncology & Carcinogenesis
  • Mice
  • Iodine Radioisotopes
  • Interleukin-13 Receptor alpha2 Subunit
  • Humans
  • Glioblastoma
  • Disease Models, Animal